FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Rhinomed Limited Stock AnalysisComprehensive stock analysis for Rhinomed Limited (RHNMF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRHNMF
RHNMF
Rhinomed Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RHNMF
Home🔹Stocks🔹Rhinomed Limited

Rhinomed Limited

RHNMF•OTC

Rhinomed Limited

RHNMF•OTC
Market cap
$5.45M
Sentiment

Your view on RHNMF

Mkt Cap
$5.45M
Sentiment
Your view
RHNMF
Rhinomed Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RHNMF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Rhinomed Limited

Industry
Medical - Devices
Sector
Healthcare
CEO
Michael Johnson
Headquarters
132 Gwynne Street, Cremorne, VIC, AU
Industry
Medical - Devices
Sector
Healthcare
CEO
Michael Johnson
Headquarters
132 Gwynne Street, Cremorne, VIC, AU
Description

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. The company's products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is headquartered in Cremorne, Australia.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News